CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation
- PMID: 16431128
- DOI: 10.1016/j.semcancer.2005.11.008
CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation
Abstract
Naturally occurring CD4+CD25+ regulatory T cells (T(reg)) are differentiated T lymphocytes actively involved in the control of peripheral immunity. Over the past few years, a number of animal studies have demonstrated the critical role of these cells in the outcome of allogeneic hematopoietic stem cell transplantation (HCT). In these models, T(reg) can exert a potent suppressive effect on immune effector cells reactive to host antigens and prevent graft versus host disease (GVHD) while preserving the graft-versus-leukemia effect (GVL). The present review summarizes current knowledge on the role of T(reg) populations in humans following allogeneic HCT. Recent investigations focusing on T(reg) in transplant patients have generated conflicting results mostly due to the use of different parameters to assess T(reg). Nonetheless, these studies suggested that an imbalance between T(reg) and effector cells during immune reconstitution can substantially impair regulatory mechanisms and contributes to the development of GVHD. Building on these studies, a number of therapeutic strategies are being developed to positively modulate T(reg) pools in vivo and prevent or even correct GVHD. Conversely, clinical interventions can also be envisaged to decrease T(reg) activity in vivo and enhance the GVL effect. These potential strategies are discussed herein. Coming years will undoubtedly yield additional knowledge on how to use T(reg) subsets in vivo and successfully control and modulate immune responses in patients post-HCT.
Similar articles
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.Biol Blood Marrow Transplant. 2006 Apr;12(4):397-407. doi: 10.1016/j.bbmt.2005.11.519. Biol Blood Marrow Transplant. 2006. PMID: 16545723
-
Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells.Bone Marrow Transplant. 2007 May;39(9):537-45. doi: 10.1038/sj.bmt.1705628. Epub 2007 Mar 12. Bone Marrow Transplant. 2007. PMID: 17351648
-
Type 1 T regulatory cells and their relationship with CD4+CD25+ T regulatory cells.Novartis Found Symp. 2003;252:115-27; discussion 127-31, 203-10. Novartis Found Symp. 2003. PMID: 14609215 Review.
-
Highly efficient expansion of human CD4+CD25+ regulatory T cells for cellular immunotherapy in patients with graft-versus-host disease.J Immunother. 2006 May-Jun;29(3):336-49. doi: 10.1097/01.cji.0000203080.43235.9e. J Immunother. 2006. PMID: 16699377
Cited by
-
Tetramerization of pyruvate kinase M2 attenuates graft-versus-host disease by inhibition of Th1 and Th17 differentiation.Hum Cell. 2024 May;37(3):633-647. doi: 10.1007/s13577-024-01033-6. Epub 2024 Feb 28. Hum Cell. 2024. PMID: 38416276
-
Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies.Int J Hematol. 2022 Apr;115(4):525-533. doi: 10.1007/s12185-021-03280-x. Epub 2022 Feb 28. Int J Hematol. 2022. PMID: 35226308
-
Reconstitution and clinical significance of T cell subsets in the early stage after related HLA-mismatched peripheral blood hematopoietic SCT without T-cell depletion in vitro.Int J Clin Exp Pathol. 2015 Aug 1;8(8):8892-901. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26464630 Free PMC article. Clinical Trial.
-
Umbilical cord blood-derived mesenchymal stem cells ameliorate graft-versus-host disease following allogeneic hematopoietic stem cell transplantation through multiple immunoregulations.J Huazhong Univ Sci Technolog Med Sci. 2015 Aug;35(4):477-484. doi: 10.1007/s11596-015-1456-8. Epub 2015 Jul 31. J Huazhong Univ Sci Technolog Med Sci. 2015. PMID: 26223913
-
Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.Biol Blood Marrow Transplant. 2013 Mar;19(3):481-5. doi: 10.1016/j.bbmt.2012.12.003. Epub 2012 Dec 12. Biol Blood Marrow Transplant. 2013. PMID: 23247045 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
